Neuland Labs Q2 results: net profit falls 46.7% to Rs 51.63 crore
Neuland Laboratories reported consolidated Q2 FY27 revenue of Rs 449.66 crore and net profit of Rs 51.63 crore in a filing with the National Stock Exchange, and approved a Rs 47.1 crore land purchase.
Key points
- Neuland Laboratories reported consolidated Q2 FY27 net profit of Rs 51.63 crore, down 46.7% from a year earlier and 65.0% from the previous quarter.
- Its consolidated revenue from operations was Rs 449.66 crore, down 12.6% year on year and 29.9% quarter on quarter, the filing shows.
- The board approved Rs 47.1 crore, including GST, to buy a land parcel in Sangareddy district for future capacity expansion, to be paid from internal accruals.
Neuland Laboratories Limited reported a consolidated net profit of Rs 51.63 crore for the second quarter of FY27, the quarter ended 30 September 2026, down 46.7% from a year earlier. Revenue from operations was Rs 449.66 crore. The company disclosed the unaudited results in a filing with the National Stock Exchange on 3 November 2026.
What Happened
The company's board approved the unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026 at a meeting on 3 November 2026. The figures below are consolidated, which include its wholly owned subsidiaries in the United States and Japan.
Revenue from operations was Rs 449.66 crore. That is 12.6% lower than the Rs 514.27 crore in the same quarter a year earlier (YoY) and 29.9% lower than the Rs 641.58 crore in the previous quarter (QoQ).
Profit for the period was Rs 51.63 crore. That is 46.7% lower than Rs 96.85 crore a year earlier and 65.0% lower than Rs 147.67 crore in the previous quarter. Profit before tax was Rs 68.98 crore, against Rs 129.44 crore a year earlier. Earnings per share were Rs 40.24, against Rs 75.49 a year earlier and Rs 115.10 in the previous quarter.
For the half year, revenue from operations rose to Rs 1,091.23 crore from Rs 807.03 crore a year earlier. Profit for the half year was Rs 199.30 crore, against Rs 110.75 crore.
The filing says the statutory auditors issued an unmodified opinion on their limited review of the results.
The board also approved capital expenditure of Rs 47.1 crore, including GST, to buy about six acres of land at Domadugu village in Sangareddy district, Telangana. The company said it will pay from internal accruals and gave the rationale as "for future capacity expansion".
What It Means
The filing shows that the company's quarterly revenue and profit were lower than both a year ago and the previous quarter, while its half-year totals remain higher than a year ago because of a stronger first quarter. The filing does not give the company's explanation for the quarterly movement in the portions available.
These are unaudited figures that were reviewed, not audited, by the statutory auditors. The filing makes no forecast. The land purchase is an approval; the filing lists the proposed capacity addition as not applicable.
Readers can see the full statements in the company's filing with the National Stock Exchange, linked with this report. Complaints against listed companies can be lodged at https://scores.sebi.gov.in.
Oquilia Data: Neuland Laboratories Ltd. (NSE: NEULANDLAB)
| Close, 2 Nov 2026 | Rs 19,575.00 (−0.63% on the day) |
|---|---|
| Return 1M / 3M / 6M / YTD / 1Y | −8.97% / +2.79% / +30.47% / +29.00% / +18.83% |
| Against Nifty 50, 1M / 3M / YTD | −13.52 / +6.66 / +39.29 points |
| 52-week closing high / low | Rs 23,995.00 (8 Sep 2026) / Rs 11,555.00 (23 Mar 2026) |
| Turnover, 20-session average | Rs 90.27 cr; 49.5% delivered; latest volume 1.4x |
| Insider trades, 90 days | none by promoters, directors or KMP |
Closes adjusted for splits and bonuses; returns exclude dividends; insider figures from BSE filings. Facts from NSE's files, not investment advice.
Full record: Neuland Laboratories share price on Oquilia
Source: Company filing on NSE
Sources & Citations
- Company filing on NSE — National Stock Exchange of India